Back to Search Start Over

A Multicenter Study To Evaluate Ceftaroline Breakpoints: Performance in an Area with High Prevalence of Methicillin-Resistant Staphylococcus aureus Sequence Type 5 Lineage.

Authors :
Khan A
Rivas LM
Spencer M
Martinez R
Lam M
Rojas P
Porte L
Silva F
Braun S
Valdivieso F
Mv Lhauser M
Lafourcade M
Miller WR
García P
Arias CA
Munita JM
Source :
Journal of clinical microbiology [J Clin Microbiol] 2019 Aug 26; Vol. 57 (9). Date of Electronic Publication: 2019 Aug 26 (Print Publication: 2019).
Publication Year :
2019

Abstract

Ceftaroline (CPT) is a broad-spectrum agent with potent activity against methicillin-resistant Staphylococcus aureus (MRSA). The sequence type 5 (ST5) Chilean-Cordobés clone, associated with CPT nonsusceptibility, is dominant in Chile, a region with high rates of MRSA infections. Here, we assessed the in vitro activity of CPT against a collection of MRSA isolates collected between 1999 and 2018 from nine hospitals ( n  = 320) and community settings ( n  = 41) in Santiago, Chile, and evaluated performance across testing methodologies. We found that our hospital-associated isolates exhibited higher CPT MIC distributions (MIC <subscript>50</subscript> and MIC <subscript>90</subscript> of 2 mg/liter) than the community isolates (MIC <subscript>50</subscript> and MIC <subscript>90</subscript> of 0.5 mg/liter), a finding that was consistent across time and independent of the culture source. High proportions (64%) of isolates were CPT nonsusceptible despite the absence of CPT use in Chile. Across methodologies, the Etest underestimated the MIC relative to the gold standard broth microdilution (BMD) test (MIC <subscript>50</subscript> and MIC <subscript>90</subscript> of 1 and 1.5 mg/liter, respectively). There was low (∼51%) categorical agreement (CA) between Etest and BMD results across CLSI and EUCAST breakpoints. The recent revision of CLSI guidelines abolished "very major error" (VME) from the previous guidelines (81%), which perform similarly to the EUCAST guidelines. The level of concordance between CLSI and EUCAST for BMD testing and Etest was >95%. Disk diffusion performed poorly relative to BMD under CLSI (CA, 55%) and EUCAST (CA, 36%) guidelines. Comparison of EUCAST to CLSI for disk diffusion (with EUCAST used as the reference) showed low agreement (CA, 25%; VME, 70%). In summary, CPT-nonsusceptible MRSA are dominant in clinical settings in Chile. Our results provide data to support the reevaluation of CPT breakpoints and to improve agreement across methodologies and agencies.<br /> (Copyright © 2019 Khan et al.)

Details

Language :
English
ISSN :
1098-660X
Volume :
57
Issue :
9
Database :
MEDLINE
Journal :
Journal of clinical microbiology
Publication Type :
Academic Journal
Accession number :
31315958
Full Text :
https://doi.org/10.1128/JCM.00798-19